2024 Canadian Urological Association guideline: Female stress urinary incontinence
- PMID: 38648655
- PMCID: PMC11034962
- DOI: 10.5489/cuaj.8751
2024 Canadian Urological Association guideline: Female stress urinary incontinence
Conflict of interest statement
COMPETING INTERESTS: Dr. Carlson has been an advisory board member for AbbVie and received honoraria for CME development. Dr. Andrews has been an advisory board member for AbbVie. Dr. Baverstock has been a speaker for Astellas and Boston Scientific; and an advisory board member/speaker for AbbVie. Dr. Nadeau has been an advisory board member for AbbVie and Astellas; a consultant for AbbVie, Boston Scientific, and Searchlight Pharma; and a speaker for AbbVie and Laborie. Dr. Welk has been a consultant for BD Company. The remaining authors do not report any competing personal or financial interests related to this work.
Figures
References
-
- Milsom I, Altman D, Cartwright R, et al. Epidemiology of urinary incontinence (UI) and other lower urinary tract symptoms (LUTS), pelvic organ prolapse (POP) and anal (AI) incontinence. In: Abrams P, Wagg A, Wein A, editors. International Consultation on Incontinence, C.L. International Continence Society; Bristol: 2017. pp. 1–142.
-
- Nambiar AK, Arlandis S, Bo K, et al. European Association of Urology guidelines on the diagnosis and management of female non-neurogenic lower urinary tract symptoms. Part 1: Diagnostics, overactive bladder, stress urinary incontinence, and mixed urinary incontinence. Eur Urol. 2022;82:49–59. doi: 10.1016/j.eururo.2022.01.045. - DOI - PubMed
LinkOut - more resources
Full Text Sources